Company* |
University/ |
Type Of |
Product Area |
Details (Date) |
| | ||||
Acambis plc |
National Institutes of Health |
Contract |
To develop a new modified vaccinia Ankara vaccine |
Acambis was awarded $9.2M for the contract (2/25) |
|
||||
Affymetrix Inc. |
Boston University Medical Center |
Collaboration |
For Affymetrix's GeneChip technology to develop a less invasive sample acquisition method and to identify pre dictive molecular signatures tha may enable screening an early detection of lung cancer in at-risk individuals |
Researchers will use GeneChip microarrays and will study the use of airway gene expression signatures for early detection, prognosis, therapy selection and monitoring of lung cancer (1/22) |
|
|
|
|
|
Allos |
Memorial Sloan-Kettering Cancer Center, Southern Research Institute and SRI International |
Licensing agreement |
For a Phase II cancer compound |
Allos licensed exclusive worldwide rights to an antifolate known as PDX (1/7) |
|
||||
Alnylam |
Max Planck Society (Germany) |
Licensing agreement |
For a series of patents in the emerging field of RNA interference |
Alnylam now has rights to develop therapeutics under the property estate in the field of RNA interference (2/12) |
|
|
|||
AlphaRx Inc. |
The Hospital for Sick Children, the University Health Network and the University of Toronto (Canada) |
Licensing agreement |
For the cancer drug VT-1 |
VT-1 can be targeted to kill malignant tumor cells and their blood supply; financial terms were not disclosed (1/28) |
|
||||
AnVil Inc.* |
National Cancer Institute |
Agreement |
To analyze NCI lung tumor databases in search of data to be used to discover gene markers for lung cancer, diagnostics, treatments and therapy |
AnVil is expected to use its domain expertise and analysis and visualization services and technologies to explore NCI gene expression data (2/3) |
|
||||
Applied |
University of California at San Francisco |
Multiyear agreement |
To study genes expressed in clinical samples |
The samples are believed to be related to immune response modulation in organ transplantation, autoimmune disease, allergy and asthma (1/7) |
|
|
|||
Arius Research Inc. (Canada; VSE:YAR) |
GI Research Unit and St. Michael's Hospital |
Collaboration |
To study antibodies and targets from colorectal tumors donated by patients |
Arius will use those tumor tissues to generate antibodies as a first step in looking for cancer drugs and targets (1/31) |
|
||||
|
Athersys Inc.*
|
University of Minnesota |
Licensing agreement |
For an adult stem cell technology discovered by Catherine Verfaillie, a professor at the university's Stem Cell Institute |
The agreement combines Verfaillie's adult stem cell technology with Athersys' discovery and development expertise and its technologies for determining protein function (12/11) |
|
||||
Avant Immuno- |
U.S. Department of Defense |
Two-year subcontract agreement |
To develop an oral, single-dose combination vaccine against anthrax and plague |
The agreement is worth up to $8M for Avant, and is a subcontract to the one between the department and DynPort Vaccine Co. LLC, a joint venture between DynCorp and Porton International Inc. (1/22) |
|
||||
Bavarian Nordic |
An undisclosed government |
Agreement |
To supply Elstree-BN smallpox vaccine |
Further details were not disclosed (2/7) |
|
||||
Bavarian Nordic |
National Institutes of Health |
Contract |
To develop its modified vaccinia Ankara vaccine |
Bavarian was awarded a three-year contract (2/25) |
|
|
|||
BD Biosciences (unit of Becton, Dickinson and Co.; NYSE:BDX) |
International AIDS Vaccine Initiative vaccine development and testing programs |
Collaboration |
To provide and validate technology for IAVI-sponsored |
Further details were not disclosed (12/3) |
|
||||
BD Biosciences |
Stanford University |
Licensing agreement |
For a technology and pending intellectual property developed by researchers at Stanford |
The technology is designed to allow scientists to use flow cytometry to detect the modified state of proteins within a signal transduction pathway (12/17) |
|
|
|||
Biophage Pharma |
Defence R&D Canada |
Co-development program |
To develop phage therapy for the treatment of anthrax and brucella infections in herds |
The program is worth C$0.5M (US$0.335M) for Biophage; it is designed to collect contaminated samples and isolate lytic phages that can kill Bacillus anthracis and Brucella spp. in the lab, purify and characterize the best candidates and run efficacy studies in a mouse model system (2/27) |
|
||||
Biopure Corp. (BPUR) |
U.S. Congress |
Research agreement |
To conduct clinical trials of Hemopure in trauma applications |
Biopure will receive about $4M in additional congressional funding (2/13) |
|
||||
Biopure Corp. (BPUR) |
U.S. Naval Medical Research Center |
Cooperative research and development agreement |
To enable the NMRC to participate in a pivotal trial of Biopure's oxygen therapeutic, Hemopure, in pre-hospital trauma |
Participation in the effort will cost the NMRC an estimated $4M; Biopure will contribute an estimated $8.7M, of which at least $643,000 will be provided during the first year (3/5) |
|
|
|||
BioSante Pharmaceuticals Inc. (OTC BB:BISP) |
U.S. Naval Medical Research Center |
Cooperative research and development agreement |
To develop a malaria vaccine |
BioSante will provide the research center with BioVant, its vaccine adjuvant and delivery system; the center will provide DNA plasmids or proteins encoding antigens for Plasmodium (1/30) |
|
|
|||
|
BioSante Pharmaceuticals
|
Wake Forest University School of Medicine
|
Licensing agreement |
For three patents encompassing combinations of hormone therapies |
The license also includes an option to use triple hormones in contraceptives (12/5) |
|
|
|||
Bruker Daltonics Inc. (BDAL) |
Mayo Clinic |
Collaboration |
To develop more efficient methods for protein analysis using Fourier transform mass spectrometry |
Bruker is providing the clinic with a 12-Tesla superconducting magnet FTMS system optimized for proteome-wide measurements (2/27) |
|
||||
Cangene Corp. (Canada; TSE:CNJ) |
Centers for Disease Control and Prevention |
Contract |
To develop a clinical-grade hyperimmune globulin that will be used to counteract a botulism toxin |
Financial terms were not disclosed (1/24) |
|
||||
Cel-Sci Corp. (AMEX:CVM) |
University of Arkansas |
Agreement |
To evaluate Cel-Sci's CEL-1000 compound for protection against chlamydia in a mouse and guinea pig genital model |
Financial terms were not disclosed (12/10) |
|
||||
Centagenetix |
Boston University and Boston Medical Center |
Research agreement |
To conduct research in the diseases of aging |
Each party will share access to its collection of genetic samples collected from centenarians; Centagenetix will gain exclusive commercial rights to resulting intellectual property and to the development and commercialization of any medical products that may result from the research (12/5) |
|
|
|||
Ceregene Inc. (subsidiary of Cell Genesys Inc.; CEGE) |
Washington University |
Exclusive, worldwide rights agreement |
For the gene expressing Neurturin, a nervous system growth factor, for use in neurological gene therapies |
It is a member of a family of proteins that can protect dopamine-producing neurons in animal models of Parkinson's disease (12/4) |
|
||||
Chiron Corp. |
American Red Cross, America's Blood Centers, Association of Independent Blood Centers and the U.S. military |
Multiyear agreements |
To supply, service and support Chiron's Procleix HIV-1/HCV Assay and System |
Details were not disclosed (11/19) |
|
||||
Chronogen Inc.* (Canada) |
McGill University (Canada) |
Licensing agreement |
For the proteins CLK-1, CLK-2 and ISP-1, as well as a series of targets |
The proteins are involved in the production of reactive oxygen species that can cause cell dam- age (11/21) |
|
||||
CliniGenetics |
K.U. Leuven Research and Development of the Catholic University of Louvain (France)
|
Licensing agreement |
To use K.U. Leuven's living-pig reference model, the minipig, for use in the cardiovascular disease field |
The minipig model exhibits physiological and metabolic characteristics similar to those in humans (2/19) |
|
|
|||
Cobra Biomanufacturing |
South African AIDS Vaccine Initiative |
Manufacturing agreement |
For a DNA vaccine against AIDS |
Cobra will supply the vaccine for Phase I/II trials, and may also supply DNA for commercial sales (12/27**) |
|
||||
Collegium |
Tufts University |
Licensing agreement |
To further develop an antibody for neutralizing specific toxins from the E. coli bacteria that cause hemolytic uremic syndrome |
Further details were not disclosed (1/10) |
|
||||
Confirmant Ltd.* (UK) |
University of Pennsylvania |
Licensing agreement |
For Confirmant's Protein Atlas of the Human Genome proteomics database |
The multiyear license gives the university access to Confirmant's database of experimentally derived, protein-coding gene and their expression in a variety of normal and disease samples (1/13) |
|
||||
Critical Therapeutics |
North Shore-Long Island Jewish Research Institute |
Licensing agreement |
For intellectual property rights to several discoveries in inflammatory therapeutics |
CTI will acquire technology and patents derived from the insti- tute's discovery that identifies the link between the central nervous system and inflamma- tory response system in humans (1/6) |
|
||||
Cyclacel Ltd.* (Scotland) |
Cancer Research Technology Ltd. (UK) and the University of Cambridge (UK)
|
Development agreement |
For tools to target validation and drug discovery based on RNA interference |
Collaboration will be funded in part by Cancer Research UK (11/18) |
|
||||
CytoGenix Inc. (OTC BB:CYGX) |
The University of Texas M.D. Anderson Cancer Center |
Collaboration |
To investigate, test and evaluate a gene believed to be related to melanoma |
The agreement with MadeleineDuvic of the university will be using the company's ssDNA Expression System to construct and deliver target-specific gene knockout sequences to melanoma cancer cells (11/26) |
|
||||
Debiopharm SA* (Switzerland) |
Tulane University |
Collaboration |
To establish the Mauvernay Research Excellence Fund |
The fund will be used for the discovery of new therapeutic agents for cancer during a three-year period (1/16) |
|
||||
|
Dentigenix LLC*
|
The Forsyth Institute, Harvard School of Dental Medicine and Massachusetts General Hospital |
Exclusive option agreement |
For Dentigenix to further develop a technology that could lead to commercial- ization of a method for regenerating teeth from an individual's own cells |
The technology is based on tissue-engineering techniques developed and successfully used at Forsyth to bioengineerporcine tooth crowns (12/19) |
|
|
|
||
DiaDexus Inc.* |
Queensland Institute of Medical Research |
Licensing agreement |
For rights related to the cancer target, Testisin |
DiaDexus will have the exclusive right to develop and commercialize therapeutic and diagnostic products using Testisin (2/12) |
|
||||
DOR BioPharma Inc. (AMEX:DOR) |
Thomas Jefferson University |
Licensing agreement |
For U.S. Patent No. 6,051,239 and corresponding international patent applications that claim the oral administration of non-toxic modified botulinum toxins as vaccines |
DOR began developing an orally administrable vaccine against botulinum toxin (2/17) |
|
||||
DOR BioPharma |
UK's Ministry of Defence |
Exclusive license |
For international patent applications covering intranasal microencapsulated vaccine technology, including anthrax and plague |
Research at the ministry showed that the vaccine technology was capable of protecting 100% of animals against lethal challenge to anthrax spores with only two intranasal administrations (1/14) |
|
||||
Elixir Pharmaceuticals Inc.* |
University of |
License |
To provide Elixir with access to discoveries in age-related genetics research, including the life span-extension discoveries around the DAF-2/insulin/IGF-1 signaling pathway in nematode worms |
Elixir obtained access to novel biological reagents; it also has a limited option to future related intellectual property that is dominated by the licensed patent rights (1/27) |
|
||||
Engevity Inc.* |
University of Florida Research Foundation Inc. |
Exclusive global agreement |
For exclusive global rights to develop Vigilant Vector |
The license also grants Engevity exclusive global rights to two products that introduce an anti-hypertensive treatment based on antimessenger RNA (3/12) |
|
||||
Epigenomics AG* |
Johns Hopkins University and Australia's Commonwealth Scientific and Industrial Research Organization Division of Molecular Science |
Access agreement |
For two new technologies for the early detection of solid tumors |
The agreements are designed to enhance Epigenomics' work in the field of DNA methylation and its role in disease detection and monitoring (1/27) |
|
||||
Focus Technologies Inc.* |
FDA |
Five-year optioned contract |
To develop a proactive and comprehensive assessment of anti-microbial resistance |
The $2.1M contract will grant the FDA access to The Surveillance Network, Focus' real-time antibiotic resistance database (11/18) |
|
||||
Galenica Pharmaceuticals Inc.* |
National Center of Biotechnology (Spain) |
Collaboration |
To develop a safe, genetically engineered subunit vaccine against smallpox |
The center will provide the viral antigens responsible for protective immunity against vaccinia virus to be formulated with Galenica's immune enhancer or adjuvant GPI-0100 (1/14) |
|
||||
GeneMax Corp. (OTC BB:GMXX) |
University of British Columbia (Canada) |
Expanded licensing agreement |
For a method to identify tumor-associated antigens |
The identification of immune dominant antigens will enable the development of cancer vaccines that can be patient specific, as well as antigens generalized across differing cancer types and patient populations (3/6) |
|
||||
Genomics Collaborative Inc.* |
Genome Institute of Singapore and the Agency for Science, Technology & Research |
Three-year agreement |
To build a DNA and tissue sample repository for the government of Singapore |
The repository, called the Singapore Tissue Network, will be linked to a clinical phenotypic database from the National Disease Registry Office, Ministry of Health, Singapore (12/9) |
|
|
|||
GenSci Regeneration Sciences Inc. (Canada; TSE:GNS) |
AlloSource |
Supply and distribution agreement |
For allograft materials belonging to Allosource |
In addition to the supply agreement, GenSci OrthoBiologics Inc. will manufacture AlloFuse DBM Putty and Gel for distribution by AlloSource to its customers (3/4) |
|
||||
GenVec Inc. (GNVC) |
U.S. Naval Medical Research Center |
Two-year contract agreement |
To use GenVec's adenovector technology for the development of vaccines against malaria and the dengue virus |
GenVec will receive $1.9M and will be responsible for constructing and producing adenovector-based vaccine candidates using its cell line and second-generation adenovector technology (1/9) |
|
|
|||
GTC Therapeutics Inc. (GTCB) |
National Institute of Allergy and Infectious Diseases |
Development agreement |
For development of a clinical-grade recombinant form of Merozoite Surface Protein 1 antigen of the Plasmodium falciparum parasite as a vaccine for malaria |
The work will include developing founder goats that express the MSP-1 antigen in their milk, as well as the downstream purification process and final product formulation (3/5) |
|
||||
Iconix Pharmaceuticals Inc.* |
FDA's Center for Drug Evaluation and Research |
Agreement |
To provide the center with access to Iconix's DrugMatrix system for evaluation purposes |
The project is designed to provide the center with experience using chemogenomic data and tools, including the application of molecular toxicology markers to predict drug actions (3/12) |
|
||||
|
Illumina Inc.
|
Cold Spring Harbor Laboratory |
Agreement |
To provide nearly 100,000 longmer oligonucleotides (oligos) for a large-scale study designed to determine the mechanism of RNA interferences |
Illumina said it is working with investigators to validate oligo design integrity and provide fast turnaround from its Oligator high-throughput DNA synthesis facility to meet the study's compressed schedule (12/3) |
|
||||
Illumina Inc. |
Genome Quebec (Canada) |
Agreement |
For the purchase of Illumina's SNP genotyping solution |
The SNP solution will be used to support Canada's contribution to the International HapMap Project, as well as genotyping projects for Genome Quebec, Genome Canada, McGill University and other Canadian academic institutions (1/9) |
|
||||
Illumina Inc. |
Wellcome Trust Sanger Institute (UK) |
Agreement |
For the purchase of Illumina's SNP genotyping solution |
The solution will be used to help the institute's work in understanding the functional implications of SNP-based sequence variation in the human genome and other model organisms (2/18) |
|
|
|||
Immunetrics |
University of Pittsburgh |
Exclusive license agreement |
For an in silico predictive software simulation process that models the inflammatory response in humans |
The inflammatory response is widely recognized as a fundamental trigger in sepsis (12/19) |
|
|
|
||
|
Ingenium Pharmaceuticals AG* (Germany)
|
German National Research Center for Environment and Health GmbH (Germany) |
Agreement |
For Ingenium to add the center's murine tissue archive to its own archive for the Ingenotyping technology platform |
The platform is a method for producing murine models with subtle gene alterations for use in the organismal validation of compounds and targets (2/3) |
|
||||
Ingenium Pharmaceuticals AG* (Germany) |
Institute for Animal Development and Molecular Biology of the Heinrich- Heine-University Dusseldorf (Germany) |
Collaboration |
To develop animal models with defined gene alterations |
The focus of the collaboration will be genes relating to limb development and neurogenesis (3/10) |
|
||||
Inimex Pharmaceuticals Inc.* and Pyxis Genomics Inc.* |
Genome Prairie (Canada) |
Agreement |
To fight pathogenic infections in both man and animal |
The project, worth C$27M (US$17.1M), will use genomics to study how pathogens affect the genes of not only hosts, but also of the pathogens themselves (11/26) |
|
|
|||
Kiadis BV* (the Netherlands) |
University of Bristol (UK) |
Collaboration |
To develop new compounds for the treatment of neuropathic pain |
Kiadis will apply its high-resolution technology to identify therapeutic molecules that bind to a target exclusively licensed to the company by the university (1/9) |
|
||||
KS Biomedix Holdings plc (UK; LSE:KSB) |
National Institute of Neurological Disorders and Stroke |
Research and development agreement |
To investigate the use of Bcl-2 proteins involved in programmed cell death in cancer treatments |
Further details were not disclosed (11/20**) |
|
||||
Large Scale Biology Corp. (LSBC) |
University of Arkansas for Medical Sciences |
Commercial biomanufacturing agreement |
To produce intervention therapy for abusers of illegal drugs |
The first target will be phencyclidine, also called PCP (2/28) |
|
||||
LaunchCyte LLC* |
Carnegie Mellon University |
Option agreement |
To license a protein isolation technology, ProteoPure |
ProteoPure is designed to help researchers in modeling the presence of disease or disease progression in humans (12/11) |
|
||||
Lynx |
Genome Institute of Singapore at the National University of Singapore |
Agreement |
For a comparative transcriptome study |
Lynx will apply its Massively Parallel Signature Sequencing technology to generate comprehensive gene expression profiles from matched samples of human, mouse and fish tissues; Lynx will receive payments for the genomics discovery services that it performs on the samples provided (3/5) |
|
||||
Medicure Inc. (Canada; TSE:MPH) inhibitors designed in conjunction with Medicure's drug discovery team |
University of Montreal (Canada) |
Collaboration |
To research the synthesis of sodium/hydrogen exchanger |
The research could lead to new cardiovascular therapeutics (12/10) |
|
||||
MedMira Inc. (Canada; VSE:MIR) |
Health Minister of the Democratic Republic of the Congo |
Agreement |
For the purchase of MedMira's rapid diagnostic products |
The order is for 1M MiraWell Triple Test units, which are designed to detect the antibodies to HIV and hepatitis B and C (3/13) |
|
|
|||
MelTec GmbH* |
Fraunhofer Institute for Applied Information Technology (Germany) |
Collaboration |
To develop an information technology platform for the management and interpretation of high-throughput experiments analyzing protein networks of whole cells in situ |
MelTec generates continuously large data sets to decipher the toponome of cells and tissues by tracing out and interpreting the context of proteins in cells (1/21) |
|
|
|||
MelTec GmbH* (Germany) |
Proteome Center Rostock (Germany) |
Collaboration |
To study rheumatoid arthritis |
MelTec and the Proteome Center, which is funded by the German Ministry for Education and Research, will apply MelTec's MELK technology to tissue samples collected from inflamed human joints (2/6) |
|
||||
Mercury Therapeutics Inc.* |
Massachusetts General Hospital |
Exclusive rights agreement |
For an oncology drug target |
Mercury will use the technology to develop small-molecule inhibitors to the Ras-Raf protein interaction (12/2) |
|
||||
MicroIslet Inc. |
The Scripps Research Institute |
Collaboration |
For islet cell transplantation therapy to treat insulin-dependent diabetes |
The parties plan to conduct pre-clinical studies using MicroIslet's technologies (3/18) |
|
||||
Migragen AG* (Germany) |
Yale University |
Exclusive licensing agreement |
For a joint patent on nerve regeneration |
The license covers worldwide rights for development and commercialization of novel therapeutics; the patent covers inhibitors of Rho (2/13**) |
|
||||
Millennium Pharmaceuticals Inc. (MLNM) |
The Cleveland Clinic |
Three-year collaboration |
To discover disease biomarkers and drug targets for the advancement of cardiovascular medicine |
The agreement will focus on capturing data to further personalized medicine efforts in specific areas of cardiovascular disease to optimize patient care (11/19) |
|
||||
|
Miraculins Inc. (Canada; VSE:MOM)
|
University of Manitoba (Canada) |
Research agreement |
For Miraculins to use the university's time-of-flight mass spectrometry laboratory |
The technique is an integral part of Miraculins' protein biomarker identification process (2/4) |
|
||||
Morphochem AG* (Germany) |
German Research Center for Biotechnology (Germany) |
Research partnership |
To develop cancer treatments based on tubulysins |
In return for exclusive access to the center's results on the class of tubulysins, Morphochem will fund the center's research activities and pay license fees if a therapeutic compound reaches the market (3/12**) |
|
||||
Nanogen Inc. (NGEN) |
Miami Children's Hospital Research Institute |
Nonexclusive licensing agreement |
For three of the most common gene mutations associated with the diagnosis of Canavan disease |
The disorder attacks an infant's brain and can result in premature death (12/11) |
|
||||
NicOx SA |
University of Michigan |
Agreement |
To study NicOx's nitric oxide-donating aspirin, NCX 4016 |
The study is funded by a $3.3M National Cancer Institute grant (3/13) |
|
||||
NovaScreen Biosciences Corp.* |
National Institute on Drug Abuse |
Agreement |
For NBC 59310 and NBC 72210 to be used in the institute's cocaine treatment program |
The institute will sponsor funding for pre-clinical and clinical development of the compounds (12/6) |
|
||||
Novozymes Biotech Inc.* (Denmark) |
U.S. Department of Energy |
Subcontract |
To develop more cost-efficient enzymes for ethanol production |
The department approved the third year of funding for the three-year subcontract (2/10) |
|
||||
Omrix biopharmaceuticals |
American Red Cross Plasma Services |
Long-term agreement |
For the marketing and distribution of a fibrin sealant product developed by Omrix |
Upon FDA approval, American Red Cross Plasma Services will market the product in the U.S. as Crosseal and will fund further clinical trials (2/24) |
|
|
|||
OSI Pharmaceuticals Inc. (OSIP) |
Cold Spring Harbor Laboratory |
Research agreement |
To use the laboratory's RNAi technology plat- form in OSI's cancer drug discovery programs |
Terms of the agreement were not disclosed (2/3) |
|
||||
|
Oxagen Ltd.* (UK)
|
University of Warwick (UK) |
Agreement |
To support a genome-wide initiative to chart functional variations in the genes for G protein-coupled receptors |
The parties were jointly awarded a £1.96M (US$3.1M) grant under the LINK Applied Genomics program (3/6) |
|
||||
Panacea |
Rhode Island Hospital/Brown University |
Extended collaboration |
To develop technology based on the enzyme human aspartyl beta- hydroxylase |
The company will continue to fund research activities at the hospital/university for three years; the company gains exclusive, worldwide commercialization rights to findings resulting from the collaboration (1/8) |
|
||||
Panvax Ltd.* |
Institut Pasteur (France) |
Collaboration |
To develop Panvax's Ctag antigen delivery technology in combination with the institute's malaria proteins |
Initial studies will be undertaken in mouse models with the human malaria parasite, Plasmodium falciparum (12/3) |
|
||||
Phytobiotech Inc.* (Canada) |
National Cancer Institute phytochemicals from PurePhytoLib |
Collaborative research and development |
To assess the anti-microbial and anti- cancer activity of agreement |
The entities will collaborate on the characterization of purified compounds (11/22) |
|
||||
Prana Biotechnology Ltd. (Australia; PRAN) |
University of Melbourne (Australia) |
Expanded agreement |
To lengthen the collaboration by two years, until 2006, while intensifying research into new drug candidates |
The original agreement was signed in May 1999 with the objective of furthering Prana's research program into underlying mechanisms of Alzheimer's disease and related neurodegenerative disorders (3/14) |
|
|
|||
Prolysis Ltd.* |
Sir William Dunn School of Pathology at the University of Oxford (UK) |
Collaboration |
To combat antibiotic-resistant bacteria |
The agreement is a three-year, US$2.5M partnership designed to produce validated antibiotic targets amenable to inhibition by small molecules, methodology to identify the biological function and pathway of genes, technology to develop assays and a tool kit of methods to identify the targets of novel antibiotics (3/3) |
|
||||
ProMetic Life |
American Red Cross Plasma Services |
Strategic alliance |
To co-develop a protein-purification process using technologies from both to recover the most valuable therapeutic proteins from plasma |
The purpose of the agreement is to provide the technology to the Red Cross and, under license, other parties; the parties each will generate royalties on the sales of the therapeutics produced from the process (2/6) |
|
|
|||
RedStorm |
University of California at San Diego |
Licensing agreement |
For RedStorm's Fyrestar technology to predict and verify protein structures |
Fyrestar will be paired with the university's Enhanced Deuterium Exchange Mass Spectroscopy technology as part of its approach to high-throughput protein structure determination (2/7) |
|
||||
Remedyne |
The Regents of the University of California that primes the immune system against diseases such as cancer or other viral and bacterial pathogens |
Exclusive, worldwide licensing agreement |
To the patent rights covering a key immune- stimulating technology |
The technology was originally developed at the University of California at Berkeley (12/3) |
|
||||
Rosetta Biosoftware (unit of Rosetta Inpharmatics Inc., a subsidiary of Merck & Co. Inc.) |
The Genomics Institute for the Novartis Research Foundation (Switzerland) |
Licensing agreement |
For the Rosetta Resolver system, a data storage, retrieval and analysis solution for gene expression data |
The institute selected the system to provide research tools across the organization that can be integrated into its environment to accelerate research (1/8) |
|
|
|||
Saegis |
Johns Hopkins University |
Multiyear research agreement |
To give Saegis exclusive access to a drug development platform designed to identify and evaluate compounds for treating age-related cognitive decline |
Saegis said it would use Parallax to evaluate its portfolio of inlicensed molecules, as well as to identify targets for development (11/19) |
|
|
|||
SIGA Technologies Inc. (SIGA) |
U.S. Army |
Contract |
To develop a smallpox antiviral drug |
The development work in the $1.6M contract will be performed at SIGA's research facility in Corvallis, Ore. (12/23) |
|
|
|||
SomaLogic Inc.* |
National Cancer Institute |
Agreement |
To develop aptamers for proteins supplied by the institute |
SomaLogic will retain the right to use the aptamers on its proteomic arrays (2/13) |
|
||||
Structural |
Hereditary Disease Foundation |
Collaboration |
To use SGX's structure-directed drug discovery technologies to investigate the structure of the protein responsible for Huntington's disease |
The agreement includes undisclosed payments to SGX for research funding, as well as success payments upon achievement of certain research milestones (12/10) |
|
||||
Switch Biotech AG* (Germany) |
Ludwig Maximilian University of Munich (Germany) |
Exclusive licensing agreement |
For a cellular target molecule and its modulators that may play a role in controlling proliferation of cells from the upper layer of the skin |
The target could lead to treatments for skin disorders such as psoriasis (2/18) |
|
||||
Sygen International plc (UK; LSE:SNI) Systems at the university |
University of New England (Australia) |
Agreement |
To establish and operate a funded chair of Genetic Information |
Further details were not disclosed (3/6) |
|
||||
Syn X Pharma Inc. (Canada; TSE:SYY) |
H.M. Dosch, at the Hospital for Sick Children (Canada) |
Collaboration |
To bring to market a therapy to prevent the onset of Type I diabetes |
The two parties discovered that a very early target of diabetic auto-immunity is not the insulin-producing beta cell, but a fine layer of nervous system tissue that surrounds those cells (1/21) |
|
||||
Syn X |
University of Ottawa Heart Institute (Canada) |
Licensing agreement |
To provide Syn X exclusive rights to develop and commercialize two patents filed by Adolfo de Bold and UOHI relating to the utility of natriuretic peptides in cardiovascular disease |
The agreement will expand the company's patent portfolio and support its commercialization position with respect to its diagnostic for congestive heart failure (12/10) |
|
|
|||
Telik Inc. |
Vanderbilt-Ingram Cancer Center |
Collaboration |
To use the company's drug discovery technology, TRAP, to discover pharmaceutically active small molecules for new cancer targets |
Further details were not disclosed (2/12) |
|
||||
Theratechnologies |
Erasmus Medical Center of Rotterdam (the Netherlands) and the University of Turin (Italy) |
Research agreement |
For a peptide that could have applications in diabetes |
Theratechnologies owns all commercial rights to the peptide and has filed an international patent application for it; the agreement involves no up-front payments; Theratechnologies will pay un- disclosed royalties if a product is commercialized (1/21) |
|
||||
Thuris Corp.* |
Chinese National Center for Drug Screening |
Collaboration |
To evaluate the therapeutic activity of the center's compounds with Thuris' RapidAging animal models |
Thuris will test kinase, protease and inflammatory inhibitors selected from the center's chemical libraries (12/4) |
|
|
|||
Transgene SA (France; TRGNY) |
International AIDS Vaccine Initiative |
Collaboration |
To manufacture preclinical lots of |
Transgene is entitled to receive payment of an undisclosed amount from IAVI (12/10) |
|
||||
VaxGen Inc. |
Chemo-SeroTherapeutic Research Institute (Japan) |
Development agreement |
To develop an attenuated smallpox vaccine for use in the U.S. |
VaxGen gains access to the vaccine, which was administered to 50,000 Japanese children who suffered no serious side effects (12/17) |
|
||||
Vion |
National Cancer Institute's Division of Cancer Treatment and Diagnosis |
Clinical trials agreement |
For the anticancer drug Triapine |
The agreement covers the conduct of future trials sponsored by the NCI to explore the activity of Triapine as a single agent or in combination with other agents in patients with cancer (1/16) |
|
||||
Wilex AG* |
San Raffaele Biomedical Science Park (Italy) |
Licensing and research agreement |
For the therapeutic and diagnostic use of the cleaved uPA receptor of the urokinasetype plasminogen activator system |
Wilex received worldwide exclusive rights to the intellectual property covering the cleaved uPA receptor in the fields of tumors and inflammatory disease; the parties will develop antibodies against the cleaved uPA receptor within the next two years (2/18) |
|
||||
Xerion Pharmaceuticals |
Tufts University |
Licensing agreement |
For cancer targets |
Xerion plans to generate therapeutic antibodies against the targets which resulted from a collaboration between Xerion and the laboratory of Daniel Jay at Tufts (2/26) |
|
||||
Xpogen Inc.* |
Sloan-Kettering Institute, the research arm of Memorial Sloan-Kettering Cancer Center |
Licensing agreement |
For PathlinX 3.0 |
Xpogen licensed PathLinx 3.0 to the Sloan-Kettering Institute, which will integrate clinical and research data to help classify cancers through the identification of new markers (2/6) |
|
|
|||
Xpogen Inc.* |
McLean Hospital |
Licensing agreement |
For PathlinX 3.0 |
Xpogen licensed PathLinx 3.0 to the McLean Hospital, which will use it to help uncover differences in gene-to-gene relationships between healthy and diseased brain tissues (2/6) |
|
||||
|
| ||||
Notes: | ||||
This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange | ||||
To read more on related topics, click on one of the words below.